Possible therapeutic targets in cardiac myocyte apoptosis

P. Andréka, Z. Nadhazi, G. Müzes, G. Szantho, L. Vandor, L. Konya, M. S. Turner, Z. Tulassay, N. H. Bishopric

Research output: Article

21 Citations (Scopus)

Abstract

Since Kerr described programmed cell death (apoptosis) as a process distinct from necrosis, there have been many studies of apoptosis in disease, especially of immunological origin. Because cardiac myocytes are terminally differentiated cells, they have typically been assumed to die exclusively by necrosis. However, during the last decade this view has been challenged by several studies demonstrating that a significant number of cardiac myocytes undergo apoptosis in myocardial infarction, heart failure, myocarditis, arrhythmogenic right ventricular dysplasia, and immun rejection after cardiac transplantation, as well as in other conditions of stress. These are potentially relevant observations, beacause apoptosis - unlike necrosis - can be blocked or reversed at early stages. Specific inhibition of this process may confer a considerable degree of cardioprotection, but requires a thorough understanding of the underlying mechanisms. Recent progress includes a better understanding of the importance of mitochondria-initiated events in cardiac myocyte apoptosis, of factors inducing apoptosis in heart failure and during hypoxia, and of the dual pro-apoptotic and anti-apoptotic effects of hypertrophic stimuli such as β -adrenoceptor agonists, angiotensin converting enzime inhibitors, nitric oxide and calcineurin. The investigation of cytoprotective and apoptotic signal transduction pathways has revealed important new insights into the roles of the mitogen-activated protein kinases p38, extracellular signal regulated kinase and c-Jun N-terminal kinase in cardiac cell fate. Our present review focuses on the intracellular signal transduction pathways of cardiac myocyte apoptosis and the possibility of specific inhibition of the process.

Original languageEnglish
Pages (from-to)2445-2461
Number of pages17
JournalCurrent Pharmaceutical Design
Volume10
Issue number20
DOIs
Publication statusPublished - 2004

Fingerprint

Cardiac Myocytes
Apoptosis
Necrosis
Signal Transduction
Therapeutics
Heart Failure
Apoptosis Inducing Factor
Arrhythmogenic Right Ventricular Dysplasia
JNK Mitogen-Activated Protein Kinases
Calcineurin
Immune System Diseases
Extracellular Signal-Regulated MAP Kinases
Myocarditis
Angiotensins
p38 Mitogen-Activated Protein Kinases
Heart Transplantation
Adrenergic Receptors
Mitochondria
Nitric Oxide
Cell Death

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Andréka, P., Nadhazi, Z., Müzes, G., Szantho, G., Vandor, L., Konya, L., ... Bishopric, N. H. (2004). Possible therapeutic targets in cardiac myocyte apoptosis. Current Pharmaceutical Design, 10(20), 2445-2461. https://doi.org/10.2174/1381612043383908

Possible therapeutic targets in cardiac myocyte apoptosis. / Andréka, P.; Nadhazi, Z.; Müzes, G.; Szantho, G.; Vandor, L.; Konya, L.; Turner, M. S.; Tulassay, Z.; Bishopric, N. H.

In: Current Pharmaceutical Design, Vol. 10, No. 20, 2004, p. 2445-2461.

Research output: Article

Andréka, P, Nadhazi, Z, Müzes, G, Szantho, G, Vandor, L, Konya, L, Turner, MS, Tulassay, Z & Bishopric, NH 2004, 'Possible therapeutic targets in cardiac myocyte apoptosis', Current Pharmaceutical Design, vol. 10, no. 20, pp. 2445-2461. https://doi.org/10.2174/1381612043383908
Andréka, P. ; Nadhazi, Z. ; Müzes, G. ; Szantho, G. ; Vandor, L. ; Konya, L. ; Turner, M. S. ; Tulassay, Z. ; Bishopric, N. H. / Possible therapeutic targets in cardiac myocyte apoptosis. In: Current Pharmaceutical Design. 2004 ; Vol. 10, No. 20. pp. 2445-2461.
@article{e1860726622049c8a83d16872905b839,
title = "Possible therapeutic targets in cardiac myocyte apoptosis",
abstract = "Since Kerr described programmed cell death (apoptosis) as a process distinct from necrosis, there have been many studies of apoptosis in disease, especially of immunological origin. Because cardiac myocytes are terminally differentiated cells, they have typically been assumed to die exclusively by necrosis. However, during the last decade this view has been challenged by several studies demonstrating that a significant number of cardiac myocytes undergo apoptosis in myocardial infarction, heart failure, myocarditis, arrhythmogenic right ventricular dysplasia, and immun rejection after cardiac transplantation, as well as in other conditions of stress. These are potentially relevant observations, beacause apoptosis - unlike necrosis - can be blocked or reversed at early stages. Specific inhibition of this process may confer a considerable degree of cardioprotection, but requires a thorough understanding of the underlying mechanisms. Recent progress includes a better understanding of the importance of mitochondria-initiated events in cardiac myocyte apoptosis, of factors inducing apoptosis in heart failure and during hypoxia, and of the dual pro-apoptotic and anti-apoptotic effects of hypertrophic stimuli such as β -adrenoceptor agonists, angiotensin converting enzime inhibitors, nitric oxide and calcineurin. The investigation of cytoprotective and apoptotic signal transduction pathways has revealed important new insights into the roles of the mitogen-activated protein kinases p38, extracellular signal regulated kinase and c-Jun N-terminal kinase in cardiac cell fate. Our present review focuses on the intracellular signal transduction pathways of cardiac myocyte apoptosis and the possibility of specific inhibition of the process.",
keywords = "Apoptosis, Cardiac myocyte, Cytoprotection",
author = "P. Andr{\'e}ka and Z. Nadhazi and G. M{\"u}zes and G. Szantho and L. Vandor and L. Konya and Turner, {M. S.} and Z. Tulassay and Bishopric, {N. H.}",
year = "2004",
doi = "10.2174/1381612043383908",
language = "English",
volume = "10",
pages = "2445--2461",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "20",

}

TY - JOUR

T1 - Possible therapeutic targets in cardiac myocyte apoptosis

AU - Andréka, P.

AU - Nadhazi, Z.

AU - Müzes, G.

AU - Szantho, G.

AU - Vandor, L.

AU - Konya, L.

AU - Turner, M. S.

AU - Tulassay, Z.

AU - Bishopric, N. H.

PY - 2004

Y1 - 2004

N2 - Since Kerr described programmed cell death (apoptosis) as a process distinct from necrosis, there have been many studies of apoptosis in disease, especially of immunological origin. Because cardiac myocytes are terminally differentiated cells, they have typically been assumed to die exclusively by necrosis. However, during the last decade this view has been challenged by several studies demonstrating that a significant number of cardiac myocytes undergo apoptosis in myocardial infarction, heart failure, myocarditis, arrhythmogenic right ventricular dysplasia, and immun rejection after cardiac transplantation, as well as in other conditions of stress. These are potentially relevant observations, beacause apoptosis - unlike necrosis - can be blocked or reversed at early stages. Specific inhibition of this process may confer a considerable degree of cardioprotection, but requires a thorough understanding of the underlying mechanisms. Recent progress includes a better understanding of the importance of mitochondria-initiated events in cardiac myocyte apoptosis, of factors inducing apoptosis in heart failure and during hypoxia, and of the dual pro-apoptotic and anti-apoptotic effects of hypertrophic stimuli such as β -adrenoceptor agonists, angiotensin converting enzime inhibitors, nitric oxide and calcineurin. The investigation of cytoprotective and apoptotic signal transduction pathways has revealed important new insights into the roles of the mitogen-activated protein kinases p38, extracellular signal regulated kinase and c-Jun N-terminal kinase in cardiac cell fate. Our present review focuses on the intracellular signal transduction pathways of cardiac myocyte apoptosis and the possibility of specific inhibition of the process.

AB - Since Kerr described programmed cell death (apoptosis) as a process distinct from necrosis, there have been many studies of apoptosis in disease, especially of immunological origin. Because cardiac myocytes are terminally differentiated cells, they have typically been assumed to die exclusively by necrosis. However, during the last decade this view has been challenged by several studies demonstrating that a significant number of cardiac myocytes undergo apoptosis in myocardial infarction, heart failure, myocarditis, arrhythmogenic right ventricular dysplasia, and immun rejection after cardiac transplantation, as well as in other conditions of stress. These are potentially relevant observations, beacause apoptosis - unlike necrosis - can be blocked or reversed at early stages. Specific inhibition of this process may confer a considerable degree of cardioprotection, but requires a thorough understanding of the underlying mechanisms. Recent progress includes a better understanding of the importance of mitochondria-initiated events in cardiac myocyte apoptosis, of factors inducing apoptosis in heart failure and during hypoxia, and of the dual pro-apoptotic and anti-apoptotic effects of hypertrophic stimuli such as β -adrenoceptor agonists, angiotensin converting enzime inhibitors, nitric oxide and calcineurin. The investigation of cytoprotective and apoptotic signal transduction pathways has revealed important new insights into the roles of the mitogen-activated protein kinases p38, extracellular signal regulated kinase and c-Jun N-terminal kinase in cardiac cell fate. Our present review focuses on the intracellular signal transduction pathways of cardiac myocyte apoptosis and the possibility of specific inhibition of the process.

KW - Apoptosis

KW - Cardiac myocyte

KW - Cytoprotection

UR - http://www.scopus.com/inward/record.url?scp=3242876085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242876085&partnerID=8YFLogxK

U2 - 10.2174/1381612043383908

DO - 10.2174/1381612043383908

M3 - Article

C2 - 15320755

AN - SCOPUS:3242876085

VL - 10

SP - 2445

EP - 2461

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 20

ER -